News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit
19 Dec 2024
byNatalia Reoutova
The 5-year update of the phase III CameL study of camrelizumab plus carboplatin and pemetrexed (C+CP) in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations demonstrates continued overall survival (OS) and progression-free survival (PFS) benefits.
19 Dec 2024








